| 1 | iNKT cells coordinate immune pathways to enable engraftment in nonconditioned hosts. (Hess NJ, S Bharadwaj N, Bobeck EA, McDougal CE, Ma S, Sauer JD, Hudson AW, Gumperz JE) Life Sci Alliance 2021 Jul;4(7) 3 Citations |
| 1 | Induction of antiinflammatory purinergic signaling in activated human iNKT cells. (Yu JC, Lin G, Field JJ, Linden J) JCI Insight 2018 Sep 06;3(17) 13 Citations |
| 1 | NNKTT120, an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease. (Field JJ, Majerus E, Ataga KI, Vichinsky EP, Schaub R, Mashal R, Nathan DG) PLoS One 2017;12(2):e0171067 25 Citations |
| 1 | Repeated Activation of Lung Invariant NKT Cells Results in Chronic Obstructive Pulmonary Disease-Like Symptoms. (Tsao CC, Tsao PN, Chen YG, Chuang YH) PLoS One 2016;11(1):e0147710 14 Citations |
| 1 | Can selectin and iNKT cell therapies meet the needs of people with sickle cell disease? (Field JJ) Hematology Am Soc Hematol Educ Program 2015;2015:426-32 5 Citations |
| 2 | A locus on mouse chromosome 13 inversely regulates CD1d expression and the development of invariant natural killer T-cells. (Tsaih SW, Presa M, Khaja S, Ciecko AE, Serreze DV, Chen YG) Genes Immun 2015;16(3):221-30 6 Citations |
| 1 | Murine splenic CD4⁺ T cells, induced by innate immune cell interactions and secreted factors, develop antileukemia cytotoxicity. (Nelles ME, Moreau JM, Furlonger CL, Berger A, Medin JA, Paige CJ) Cancer Immunol Res 2014 Nov;2(11):1113-24 9 Citations |
| 1 | NF-κB is activated in CD4+ iNKT cells by sickle cell disease and mediates rapid induction of adenosine A2A receptors. (Lin G, Field JJ, Yu JC, Ken R, Neuberg D, Nathan DG, Linden J) PLoS One 2013;8(10):e74664 24 Citations |
| 1 | Expression of CD1c enhances human invariant NKT cell activation by α-GalCer. (Fox LM, Miksanek J, May NA, Scharf L, Lockridge JL, Veerapen N, Besra GS, Adams EJ, Hudson AW, Gumperz JE) Cancer Immun 2013;13:9 11 Citations |
| 2 | Genetic control of murine invariant natural killer T cells maps to multiple type 1 diabetes regions. (Tsaih SW, Khaja S, Ciecko AE, MacKinney E, Chen YG) Genes Immun 2013 Sep;14(6):380-6 4 Citations |
| 1 | Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. (Field JJ, Lin G, Okam MM, Majerus E, Keefer J, Onyekwere O, Ross A, Campigotto F, Neuberg D, Linden J, Nathan DG) Blood 2013 Apr 25;121(17):3329-34 79 Citations |
| 2 | Genetic control of murine invariant natural killer T-cell development dynamically differs dependent on the examined tissue type. (Chen YG, Tsaih SW, Serreze DV) Genes Immun 2012 Feb;13(2):164-74 15 Citations |
| 1 | Targeting iNKT cells for the treatment of sickle cell disease. (Field JJ, Nathan DG, Linden J) Clin Immunol 2011 Aug;140(2):177-83 38 Citations |
| 1 | Testing the role of P2X7 receptors in the development of type 1 diabetes in nonobese diabetic mice. (Chen YG, Scheuplein F, Driver JP, Hewes AA, Reifsnyder PC, Leiter EH, Serreze DV) J Immunol 2011 Apr 01;186(7):4278-84 27 Citations |
| 1 | A recombinant heavy chain antibody approach blocks ART2 mediated deletion of an iNKT cell population that upon activation inhibits autoimmune diabetes. (Scheuplein F, Rissiek B, Driver JP, Chen YG, Koch-Nolte F, Serreze DV) J Autoimmun 2010 Mar;34(2):145-54 27 Citations |
| 5 | Impaired survival of peripheral T cells, disrupted NK/NKT cell development, and liver failure in mice lacking Gimap5. (Schulteis RD, Chu H, Dai X, Chen Y, Edwards B, Haribhai D, Williams CB, Malarkannan S, Hessner MJ, Glisic-Milosavljevic S, Jana S, Kerschen EJ, Ghosh S, Wang D, Kwitek AE, Lernmark A, Gorski J, Weiler H) Blood 2008 Dec 15;112(13):4905-14 49 Citations |
© 2023 Clinical & Translational Science Institute